Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent.
about
Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer.Characterization of an N-Terminal Non-Core Domain of RAG1 Gene Disrupted Syrian Hamster Model Generated by CRISPR Cas9.Designer Oncolytic Adenovirus: Coming of Age.CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge
P2860
Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Re-designing Interleukin-12 to ...... tumor immunotherapeutic agent.
@en
Re-designing Interleukin-12 to ...... tumor immunotherapeutic agent.
@nl
type
label
Re-designing Interleukin-12 to ...... tumor immunotherapeutic agent.
@en
Re-designing Interleukin-12 to ...... tumor immunotherapeutic agent.
@nl
prefLabel
Re-designing Interleukin-12 to ...... tumor immunotherapeutic agent.
@en
Re-designing Interleukin-12 to ...... tumor immunotherapeutic agent.
@nl
P2093
P2860
P1476
Re-designing Interleukin-12 to ...... -tumor immunotherapeutic agent
@en
P2093
Baisui Feng
Dongling Gao
Guozhong Jiang
Hongtao Liu
Jianzeng Dong
Jiwei Wang
Nicholas R Lemoine
Pengju Wang
Shengdian Wang
P2860
P2888
P356
10.1038/S41467-017-01385-8
P407
P577
2017-11-09T00:00:00Z
P6179
1092522904